SJS Investment Consulting
MPLT icon

SJS Investment Consulting’s MapLight Therapeutics MPLT Stock Holding History

SJS Investment Consulting’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-18
Closed -$646 – 3366
2026
Q2 		$646 Buy
+18
New +$518 ﹤0.01% 2182

Other funds holding MPLT

Market Street Wealth Management Advisors
Market Street Wealth Management Advisors Indianapolis, Indiana $703M AUM 10.22% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

SJS Investment Consulting's MPLT Position: Q3 2026 in Review

SJS Investment Consulting sold out of MapLight Therapeutics (MPLT) in Q3 2026, closing a stake of 18 shares — an estimated $646 sold.

SJS Investment Consulting first reported a position in MPLT in Q2 2026 and held it in 1 quarter. The position peaked at $646 in Q2 2026. 10 funds tracked by Wall St. Rank hold MPLT as of Q3 2026.

  • SJS Investment Consulting reported no remaining MapLight Therapeutics position as of Q3 2026 after selling out during the quarter.
  • SJS Investment Consulting sold 18 MapLight Therapeutics shares in Q3 2026, an estimated $646.
  • SJS Investment Consulting first reported a position in MapLight Therapeutics in Q2 2026 and held it in 1 quarter.
  • SJS Investment Consulting's MapLight Therapeutics position peaked at $646 in Q2 2026.
  • 10 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.